Anthropic, the brains behind Claude AI, recently announced a breakthrough. Their model has designed working mini-proteins that could form the basis of new drugs—something that usually takes specialists months to do.
Claude nailed it for 14 out of 15 cases, according to Anthropic. These proteins can bind to disease-causing pathogens and neutralize them—a key step in drug development.
But the numbers here come straight from Anthropic themselves—no independent experts have verified this yet. That said, Claude's success rate ranges from 22% to 35%, which is impressive compared to typical industry standards of 10-15%. Some designs even outperformed previously published results.
Interestingly, the physical lab work wasn't handled by Anthropic either. Two external parties synthesized and tested these proteins. The whole process still takes weeks—no matter how smart the software is.
The Dull Work Gets Faster Too
In a separate trial, Claude's Opus 5 model could read chemical measurements in just 25 minutes. That’s a job usually done by chemists manually over hours—and even took four days for an external lab this time around.
Opus 5 even corrected its own mistake during the process—an impressive feat that you’d typically expect from a meticulous colleague rather than an AI system.
A Personal Quest
This work is more than just about numbers. Anthropic’s CEO, Dario Amodei, who lost his father to hepatitis C before effective treatment was available, sees this as a chance for AI to help cure many diseases within five to ten years.
But he also recently toned down expectations on X, noting that the industry hasn’t yet delivered on its big promises. Real progress in treating diseases, not slick marketing campaigns, will earn back trust.
The Dark Side of Progress
There's a flip side to this innovation. Anthropic highlights how the same technology that could speed up drug development could also be used for nefarious purposes like bioweapons creation. To avoid misuse, they restrict access to their most powerful models only to screened researchers.
The Long Road Ahead
While these results are exciting, it's worth noting that designing a protein is just the first step towards creating an actual drug. Anthropic acknowledges this too. The journey from lab bench to pharmacy counter is still long and winding—but AI is definitely making strides.